Draupnir Bio
Joachim Pold Vilstrup is the co-founder of Muna Therapeutics since January 2020. Joachim Pold also served as the Head of Protein Chemistry at Muna Therapeutics starting from May 2020. Additionally, they are the Head of Drug Discovery at Draupnir Bio starting from January 2020.
Joachim Pold Vilstrup completed their education at Aarhus University. From 2016 to 2020, they pursued a Doctor of Philosophy (PhD) degree in Biochemistry and Molecular Biology. Prior to that, they obtained a Master of Science (M.Sc.) degree in Molecular Biology, during the period of 2010 to 2016.
This person is not in any teams
Draupnir Bio
Draupnir Bio intends to develop a new type of cholesterol-lowering medicine that prevents blood clots in the heart more effectively than the current medicine. The company is developing a platform for exploring the glycome to develop novel therapeutics, based on array technology, protein chemistry, and advanced carbohydrate chemistry. The company isable to synthesize, screen, and select highly potent and specific heparan sulfate glycomimetic drug candidates in cardiovascular, inflammatory, and infectious diseases.